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Protein C inhibitor (PCI) is a plasma serine proteinase 
inhibitor (serpin) that is a major  physiological regulator 
of activated protein C. Inhibition of its target proteinase 
is accelerated by heparin in a reaction that involves the 
binding of both inhibitor and proteinase to heparin to 
form a ternary complex. This study was undertaken to 
understand the role of the H helix  region (residues 264- 
278) of PC1 in heparin binding and used (i) a recombi- 
nant truncated PC1 fusion protein of the first 294 resi- 
dues, (ii) H helix synthetic peptides containing single 
ArglLys + Glu substitutions, and (iii) site-directed Ala 
mutagenesis of 4 basic residues (Arg-269,  Lys-270,  Lys- 
276, and Lys-277) in the H helix  region of full-length re- 
combinant PC1 (rPCI) expressed in Buculouirus. The 
PC1 fusion protein interfered in heparin-accelerated 
PCI-proteinase inhibition reactions, and it bound to 
heparin-Sepharose.  Compared to the wild-type PC1 fu- 
sion protein, deletion of the H helix  from the fusion pro- 
tein resulted in a reduction of both heparin-Sepharose 
binding and the ability to compete  for heparin during 
PCI-proteinase inhibition reactions.  Competition  assays 
with H helix synthetic peptides revealed that  the R269E 
altered peptide was the least effective at blocking  hep- 
arin-catalyzed PCI-proteinase inhibition reactions. 
Compared  with  full-length  active  wild-type  rPCI, R269A 
K270A and K276A:K277A rPCI  both had reduced hepa- 
rin-Sepharose binding, but only  R269AK270A rPCI 
showed a loss of heparin-accelerated proteinase inhibi- 
tion  for  both activated protein C and thrombin. We con- 
clude that a major heparin-binding site of  PC1 is the H 
helix,  unlike its heparin-binding serpin homologues an- 
tithrombin and heparin cofactor 11, which  bind heparin 
primarily through the D helix. 
Protein C inhibitor (PCI)’ is a plasma glycoprotein that is a 
major physiological regulator of the  anticoagulant  proteinase 
activated  protein C  (APC) (for a review, see Refs. 1 and 2). In 
addition to  activated  protein C, PC1 can also inhibit  thrombin 
and  several  other  proteinases involved in coagulation,  fibrin- 
can Heart Association-Sanofi Winthrop (to F. C. C.), Research Grant 
* This  work  was  supported in part by a grant-in-aid from the Ameri- 
HL-06350 from the National Institutes of Health (to F. C. C.),  Grant 
92.306  from the Netherlands  Heart  Foundation (to J. C. M. M.),  and a 
fellowship  from the Royal Netherlands Academy ofArts and Sciences (to 
J. C. M. M.), The  costs of publication of this article were  defrayed  in 
part by the payment of page  charges.  This  article  must  therefore be 
hereby marked “advertisement” in accordance with 18 U.S.C. Section 
1734  solely  to indicate this fact. 
11 To whom  correspondence  and reprint requests should be addressed: 
University of North Carolina, Chapel Hill, NC 27599-7035. Fax: 919- 
Div. of Hematology, Campus Box 7035, 416 Burnett-Womack Bldg., 
966-7639;  E-mail: fchurch@uncvxl.oit.unc.edu 
The  abbreviations  used are: PCI,  protein C inhibitor;  rPCI, recom- 
binant PCI;  APC, activated  protein C; serpin,  serine  proteinase  inhib- 
itor; PEG,  polyethylene  glycol;  BSA,  bovine  serum albumin; MBP, malt- 
ose-binding  protein. 
olysis, and reproduction (3-9). PC1 is a member of the  serine 
proteinase inhibitor (serpin) superfamily of proteins (lo), of 
which a,-proteinase inhibitor is the prototype (11). Like the 
serpins  antithrombin  and  heparin cofactor 11, the reaction of 
PC1 with some of its  target  proteinases  is accelerated by hep- 
arin  and  other glycosaminoglycans (3,12).  Heparin-accelerated 
thrombin  inhibition by these  three  serpins  appears to follow 
the  template model, in which both  serpin  and  proteinase  bind 
to heparin to form a ternary complex (13-18). However, the 
heparin-induced  rate  increase  is modest  for PC1 compared with 
antithrombin  and  heparin cofactor I1 (18). 
The location of the  heparin-binding  site  in PC1 is still  unre- 
solved. Heparin-binding  proteins  are known to  contain  clusters 
of basic amino acid residues  that form centers of high positive 
charge  density  and  that form electrostatic  interactions with the 
acidic groups of heparin (19). Three regions in the primary 
structure of PC1 contain  clusters of basic amino acids: residues 
1-11, 82-90, and 266-278. Based on PC1 molecular  modeling 
studies, Kuhn et  al. (20) proposed that a large positively 
charged  heparin-binding  surface is formed by the  juxtaposition 
of the first 15 amino-terminal amino acids (termed the A+ 
helix)’ with  the H  helix  region (residues 264-278).’ A role for 
the A+ helix in  heparin  binding  was  supported by demonstrat- 
ing  that  an anti-PC1  antibody mapped to the A+ helix blocked 
heparin-Sepharose  binding (20). We provided  evidence that  the 
H helix in PC1 binds  heparin by showing that a H helix  syn- 
thetic peptide bound to  immobilized heparin and interfered 
with  heparin-catalyzed  serpin-proteinase  inhibition  reactions 
(12). In  contrast,  an A+ helix synthetic  peptide  and a peptide 
containing PC1 residues 82-90 were  less effective a t  blocking 
heparin-catalyzed  PCI-proteinase  inhibition  reactions (12). 
The work presented  here provides  more compelling evidence of 
a role for the H  helix in  heparin  binding  to PCI. We have used 
a recombinant  truncated PC1 fusion protein expressed in bac- 
teria,  altered  synthetic peptides, and site-directed mutagenesis 
of full-length  recombinant PC1 expressed in Baculovirus t o  ex- 
amine  the H  helix of PCI. 
EXPERIMENTAL PROCEDURES 
Materials-Oligonucleotide primers were  purchased  from the oligo- 
nucleotide  synthesis  facility of the Department of Pathology,  University 
of North  Carolina  (Chapel  Hill, NC) or from  National  Biosciences. Re- 
striction enzymes were from Promega or New England Biolabs Inc. 
Moloney  murine  leukemia virus  reverse transcriptase, T4 DNA ligase, 
and mung  bean  exonuclease  were  obtained  from Life Technologies,  Inc. 
Taq DNA polymerase and T4  polynucleotide  kinase  were  from  Promega, 
and T4 DNA polymerase  and isopropyl-P-D-thiogalactopyranoside were 
from  Boehringer  Mannheim.  The  Sequenase  version 2.0 DNA sequenc- 
ing kit was  from  United States Biochemical  Corp.  Plasmid  pMAL-c2, 
Escherichia coli strains TB1 and PR700, amylose resin, and bovine 
Structural regions designated for PC1 and all other serpins de- 
scribed here are based on the elements delineated from the three- 
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factor Xa were  purchased from New England Biolabs Inc.  E. coli BW313 
was a kind  gift of Dr. Elmer M. Price  (Department of Pharmacology, 
University of North  Carolina,  Chapel  Hill). 4-(2-Aminoethyl)benzene- 
sulfonyl fluoride  HCl  was from Calbiochem, and  leupeptin, polyethyl- 
ene glycol (PEG) 8000, Polybrene (1,5-dimethyl-1,5-diazaundecameth- 
ylene  polymethobromide), and bovine serum  albumin (BSA) were from 
Sigma. The following proteinase chromogenic substrates were used: 
tosyl-Gly-Pro-Arg-p-nitroanilide (Chromozym TH; Boehringer Mann- 
heim) for thrombin  and Lys-benzyloxycarbonyl Pro-Arg-p-nitroanilide 
(Spectrozyme  PCa;  American  Diagnostica  Inc.) for APC. Human 
a-thrombin  was  purified as described previously (21), and  human APC 
was purchased from Haematologic Technologies Inc. Human plasma 
PC1 was  purified as described  (22)  with modifications involving affinity 
chromatography on an  anti-PC1 monoclonal antibody column instead of 
DEAE-Sepharose  fractionation.  Human  plasma  antithrombin  was  pu- 
rified as described previously (23). Unfractionated heparin was ob- 
tained from Diosynth (Oss, The  Netherlands).  Heparin-Sepharose  was 
purchased  from  Pharmacia Biotech Inc. 
Production of Duncated  PCI  Fusion Protein-PC1 cDNA was ob- 
tained by first-strand cDNA synthesis of HepG2 (a  hepatoma cell line) 
total RNA using a random  hexameric oligonucleotide primer, followed 
by polymerase  chain  reaction  amplification  with two PCI-specific oligo- 
nucleotides that  omitted  the  signal  sequence  and  engineered  5'-  and 
3'-NcoI restriction  sites (5'-TCCTCCATGGCTCACCGCCACCACCCC- 
CGGGA-3' and 5'"ITITCCATGGGAGAAGCCCCACCTCAGGGGCG- 
3').  The PC1 cDNA was  subcloned  into  phagemid pSL1190 to  add 5'- 
EcoRI and 3'-BarnHI flanking sequences, which permitted insertion 
into M13mp19 for  mutagenesis.  The oligonucleotide-directed mutagen- 
esis  method of Kunkel  et al. (24)  was  used. Briefly, uracil-rich  single- 
stranded DNA was  obtained by infection of E. coli strain BW313 with 
recombinant PCI/M13mpl9 phage. The purified DNA was used as a 
template  for  in  vitro  annealing  and  elongation of a mutagenic oligonu- 
cleotide (5'-GCTCCTATCAGT_GAGAGAAAGTCC-3') that incorporated 
a  stop codon at  position 987-989 (lo), corresponding  to  residue 295 in 
PCI. E. coli strain DH5aF' was transformed with the heteroduplex 
DNA. A mutant clone was selected and fully sequenced using the 
dideoxynucleotide chain termination method (33) (Sequenase  version 
2.0). This modified cDNA(termed PCI,,,) was excised from M13mp19 by 
NcoI digestion, treated with mung bean exonuclease to remove the 
sticky  ends, and  ligated  into  the  XmnI  site of pMAL-c2, a  prokaryotic 
vector that expresses foreign DNA as a fusion protein with E. coli 
maltose-binding  protein (MBP). E. coli strain  TB1  was  transformed by 
electroporation.  A clone was  selected  that  contained  the PCI,,, insert  in 
the correct  orientation  and  reading  frame  and  that  was  missing  the 
amino-terminal codon for alanine  that  resulted from the engineered 
NcoI site (PC12,,/pMAL-2c) (see  Fig. 1). 
PCIz9, helix  deletion mutants were  also  generated by using  the oli- 
gonucleotide-directed  mutagenesis  method of Kunkel  et  al.  (24) on DNA 
cassettes removed from PCI2,,/pMAL-2c and  inserted  into M13mp19, a 
Sad-KpnI DNA fragment for the A+ helix  deletion, and a KpnI-BanHI 
fragment for the H  helix  deletion. Coding sequence for the A+ helix (ami- 
no acids 1-15  of the  mature  protein)  was  deleted  using  a  30-mer com- 
posed of the 15 nucleotides 5' and  3'  to  the 45 bases  being  deleted (5'- 
GGGATCGAGGGAAGGCATGTAGGTGCCACG-3'). Coding sequence 
for PC1 amino acid residues 264-277 (H helix  region)  was  deleted  using 
a similarly  designed oligonucleotide (5"GTGGAGAATGGACTGAG- 
GCAGCTGAGCTT -3'). Mutated cassettes were fully sequenced and 
subcloned  back  into  the PCI2,,/pMAL-2c expression vector to  replace the 
corresponding  wild-type  sequence.  The AA+ helidAH  helix double mu- 
tant  was  constructed by replacing the wild-type Sad-KpnI  cassette  in 
AH-PC12,,/pMAL-2c with  the  mutant AA+skPCI,,, cassette, 
For  large-scale  fusion  protein  production, the expression vector con- 
structs  were  transformed  into  E. coli strain PR700. Fusion  protein  was 
purified from cell extracts by amylose resin affinity chromatography 
according  to  the  manufacturer's  procedure.  The  purified  fusion  proteins 
were  dialyzed  into  20 mM HEPES, 10 m~ NaCl, 0.1% PEG, 1 mM NaN,, 
pH 7.4, and  their  concentrations  were  determined by the dye binding 
assay of Bradford  (32)  using  BSAas  the  standard.  Immunoblots sh wed 
that  the wild-type and AH helix fusion proteins were detected by a 
monoclonal antibody to the A+ helix of PCI,  while the AA+ helix  and 
PA+ helidAH  helix  fusion  proteins  were  not  (data  not  shown). 
Baculovirus Expression of Full-length rPCI-Wild-type rPCI was 
generated  and  characterized as described  previously  (25). H helix  sub- 
stitution  mutants  were  generated as follows. A  1-kilobase DNA cassette 
containing  the  3'-end of PC1 cDNA  followed  by 500 base  pairs of the 
transfer vector pVL1393 downstream of the polylinker  was excised from 
PCYpVL1393 by limited  KpnI  digestion  and  subcloned  into M13mp19 
for  mutagenesis  using  the  method of Kunkel  et  al.  (24). Oligonucleotide 
5'-GAGAAAACGCTGGCGGCGTGGCTT.MGATG-3' was employed to 
replace Arg-269 and Lys-270 with  alanines  (R269AK270A  rPCI),  and 
oligonucleotide 5'-C'M'AAGATG'I"I'CGCAGCGAGGCAGCTCGAG-3' 
was  used  to  replace Lys-276 and Lys-277 with  alanines (K276A:K277A 
rPCI). At the same time, the internal KpnI site from the vector 
polylinker was modified (made uncuttable) with oligonucleotide 5'- 
GGATCCCGGGTATATTCTGAATTCC-3' to  facilitate cloning back into 
the PCYpVL1393 transfer vector construct.  Mutant  cassettes  were  se- 
quenced and subcloned back into PCVpVL1393 to replace wild-type 
DNA, and  the  transfer vector was  sequenced  again  to confirm the pres- 
ence of the desired  substitutions  prior  to homologous recombination. 
Generation of high titer  recombinant  viral  stocks  and  infection of High- 
Fivem cells (Invitrogen)  were  performed as described previously (25). 
Wild-type rPCI  was  purified by batch  absorption  to  heparin-Sepharose 
as  detailed (25). H  helix mutants were  purified  with the following modi- 
fications.  Conditioned  medium  was  diluted 1:2 with 20 mM HEPES,  10 
mM NaCl, 0.1% PEG, 0.02% NaN,, pH 6.5, to  lower the ionic strength 
before batch  absorption  to  heparin-Sepharose.  The  resin  was  washed 
twice with  this  HEPES buffer, pH 6.5, containing  150 mM NaCl  and once 
with  this  buffer  containing 250 mM NaCl before elution  with 1 M NaCl 
in  HNPN  buffer  (20 mM HEPES, 150 mM NaCl,  0.1%  PEG,  0.02% NaN,, 
pH 7.4). The  proteins  were  dialyzed  into  HNPN  buffer  and  quantitated 
by enzyme-linked  immunosorbent  assay and  thrombin  inhibition  rate 
constants  in  the  absence of heparin. Typical protein yields from 50  ml of 
culture  medium  (from two T-150 flasks of confluent  High-FiveTM  cells) 
were 70 pg of wild-type  rPCI  and  15-40  pg of the H helix mutants. 
Competition Assays-Fusion protein  competition  in  proteinase  inhi- 
bition  assays  was  performed at ambient  temperature  in 96-well micro- 
titer  plates  under  pseudo  first-order  conditions.  Increasing  concentra- 
tions (0.05-5 PM) of fusion  protein  or  MBP  alone  were  added to assay 
mixtures containing inhibitor, 1 pg/ml heparin,  and  2 mg/ml BSA in 
HNPN buffer. Reactions were started by the addition of proteinase. 
Inhibitor-proteinase concentrations used were 50 nM PC1 and 5 nM 
thrombin,  100 nM PC1 and  10 nMAPC, and 10 nM antithrombin  and 1 nM 
thrombin.  After  incubation,  remaining  proteinase  activity  was  meas- 
ured by hydrolysis of 0.15 mM chromogenic substrate with 2 mg/ml 
Polybrene.  Second-order  proteinase  inhibition rate  constants (k,) were 
calculated as -ln(a)/t[Il,  where a is  the  fractional  proteinase  activity 
remaining  relative  to  the  uninhibited control, t  is  the  incubation  time, 
and  [I]  is  the  inhibitor  concentration. Fig. 2 plots relative proteinase 
activity (a) as a  function of increasing fusion protein  concentrations. 
Because  relative  thrombin  activity  in  the  presence of inhibitor  but  in 
the absence of fusion protein (i.e. no fusion protein control, min a )  
ranged from 0.15 to  0.3  in  multiple  assays,  the  data  were  normalized by 
fixing the min a value at 0.2 as follows: normalized a = 0.2 + 0.8(old a 
- old min  all(1.0 - old min a) .  Control  experiments verified that fusion 
proteins did not inhibit proteinase chromogenic activity and did not 
affect proteinase  inhibition in  the absence of heparin. 
PC1 H helix synthetic peptides for competition assays were as- 
sembled by CDI (Lelystad,  The  Netherlands).  Purity  was >85% by high 
pressure liquid chromatography.  Peptides (0.1-500 PM) were  added to 
assay  mixtures  containing  40 IIM PC1 (with APC) or 5 nM PC1 (with 
thrombin), 0.5% BSA, and  10 pg/ml heparin  in 50 mM Tris-HC1, 125 mM 
NaC1, 0.1% PEG 6000, 2 mM CaCl,, pH 7.4. Reactions  were performed 
at 25 "C and  started with the addition of 4 nM APC or 100 PM thrombin. 
After  incubation, the  remaining chromogenic activity  was  measured by 
adding 0.5 mM S-2366 to the  assay  mixture.  The  rate of p-nitroaniline 
formation was linearly related to the free proteinase concentration. 
Control  experiments verified that none of the peptides affected protein- 
ase chromogenic activity or the  ability of PC1 to  inhibit APC or thrombin 
in  the absence of heparin. 
Heparin-Sepharose Affinity Chromatography-The relative affinity 
of recombinant  and  plasma  PCIs for immobilized heparin  was  deter- 
mined  using the  fast  protein  liquid  chromatography  system of Pharma- 
cia Biotech Inc. and a  1-ml  heparin-Sepharose column. Samples  were 
loaded in 20 mM HEPES, 10 mM NaC1, 0.1% PEG,  pH 7.4, and  eluted 
with  a  linear  1.5  mumin  salt  gradient of 10 mM to 1.2 M NaCl.  120  pg of 
the fusion  proteins  were  loaded,  and  elution  was  monitored by contin- 
uous  absorbance a t  280 nm  readings. 0.5 pg of full-length  rPCI  was 
loaded, 30 x 1-ml  fractions  were collected, and  the  fractions  were  ana- 
lyzed by enzyme-linked  immunosorbent  assay.  The salt  gradient  and 
elution profile were  plotted,  and  the  salt  concentration at which peak 
elution  occurred  was  calculated.  The  mean of five to  seven runs on two 
separate  columns  is  reported for the fusion proteins,  and  the  mean of 
three  runs  is  reported for full-length  rPCI  and  plasma  PCI. 
Heparin-accelerated  Proteinase  Inhibition by Full-length  rPCI  and 
Mutants-Inhibition  assays  were  performed a t  ambient  temperature  in 
BSA-coated 96-well microtiter  plates  and  contained 5 nM rPCI  and 0.5 
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FIG. 1. Cloning  and  mutagenesis of rPCI-(1-294) fusion pro- 
teins in E. coli. PC1 cDNA was modified by the oligonucleotide-di- 
rected  mutagenesis  method of Kunkel  et  al.  (24)  to  incorporate a stop 
codon at  nucleotide 986, corresponding to amino acid 295  in  PCI.  The 
cDNA was  inserted  into pMAL-c2 at the  XmnI  site  to  create PCI,,,J 
pMAL-c2. A+ helix  and  H  helix  deletion fusion mutants were  generated 
from the  parent  expression  construct by mutagenesis of DNA cassettes 
removed from PCI,,,/pMAL-c2 as described under  “Experimental  Pro- 
cedures.’’ Fusion  proteins  were  expressed  in E. coli and  purified by af- 
finity  chromatography on amylose resin. mcs, multiple cloning site; bp, 
base  pairs; w.t., wild-type. 
nM thrombin (or 10 nM rPCI  and 1 nM APC),  0.1 mg/ml Polybrene or 
various  concentrations of heparin,  and 2 mg/ml BSA in HNPN buffer. 
Reactions  were  started  with  the  addition of proteinase,  and  after  incu- 
bation, the  remaining  proteinase  activity  was  measured  with 0.15 mM 
chromogenic substrate  containing  2 mg/ml Polybrene. Second-order in- 
hibition rate  constants  were  calculated  as described above. Each  assay 
consisted of triplicate determinations, and the mean inhibition rate 
from  three  separate  assays is reported.  For  each  mutant,  preparations 
from two separate clones were  analyzed  and  gave  comparable  results. 
RESULTS 
Recombinant PCI-(1-294) Fusion Proteins-A recombinant 
PC1 fragment with both A+ and H helices but lacking the  re- 
active-site loop region (therefore possessing no inhibitory ac- 
tivity)  was  expressed in E. coli as a fusion protein  with MBP 
and  is designated “wild-type” PCI-(1-294) fusion protein. Three 
helix deletion mutants were also constructed in which residues 
1-15  of PC1 (A+ helix), residues 264-277 (H helix), or both the 
A+ and H helices were deleted, and they are designated AA+ 
helix, AH helix, and AA+ helix/AH helix fusion proteins, respec- 
tively (Fig. 1). To measure  the effect of helix deletions on hep- 
arin binding by PCI-(1-294) fusion protein,  increasing concen- 
trations of fusion protein were added to an assay system 
containing  thrombin,  plasma-derived  PCI, and-heparin. A  hep- 
arin-binding  protein would  be expected to compete with plasma 
PC1 for heparin,  thereby decreasing the  rate of proteinase in- 
I 
FIG. 2. Effect of helix deletions  on  fusion  protein  competition 
in heparin-accelerated thrombin inhibition. Increasing  concentra- 
tions of wild-type fusion  protein (0) or AH helix ( 0  1, AA+ helix (01, or 
AA+ helix/AH helix (A) deletion  fusion  proteins  were  added  to  thrombin 
inhibition assays containing 50 nM PCI, 5 nM thrombin,  and 1 pg/ml 
heparin.  After  incubation,  the  remaining  thrombin  activity  was  meas- 
ured by tosyl-Gly-Pro-Arg-p-nitroanilide hydrolysis. The y axis  shows 
thrombin activity relative to  the activity in the absence of PCI. In- 
creased thrombin activity indicates decreased inhibition  due to compe- 
tition between PCI and fusion protein for heparin  binding.  The  mean of
normalized data from  three  separate  experiments is presented. 
hibition. Wild-type PCI-(1-294) fusion protein blocked heparin- 
accelerated  thrombin  inhibition in a dose-dependent manner 
(IC5,, = 1 VM) (Fig. 2). Free MBP alone or wild-type fusion 
protein in  the absence of heparin did not have this property 
(data not shown). The AA+ helix fusion protein had a dose- 
response  curve much like that of the wild-type fusion protein, 
but both the AH helix and AA+ helix/AH helix fusion proteins 
had a  drastically reduced ability to compete with  plasma PC1 
for heparin binding (Fig. 2). 
The fusion proteins were also assayed for their effect on 
heparin-accelerated APC inhibition by  PC1 and thrombin inhi- 
bition by antithrombin. For both inhibitor-proteinase pairs 
tested at  a fixed concentration of 3 p~ fusion protein and 1 
yg/ml heparin (k, = 18.9 x lo4 M - ~  min-’ for PCI-APC and 18.4 
x lo8 M-’ min” for antithrombin-thrombin in the absence of 
fusion proteins), the addition of the wild-type or AA+ helix 
fusion protein reduced the  rate of proteinase  inhibition by both 
serpins to  -9 or -16%, respectively, of the inhibition rate  in  the 
absence of fusion  protein. In  contrast,  the AH helix fusion pro- 
tein competed less effectively, reducing the  rate of heparin- 
accelerated  proteinase  inhibition by both serpins  to -53% of 
the  rate  without fusion  protein present. The wild-type fusion 
protein and all three helix deletion fusion proteins also bound 
to heparin-Sepharose. In  contrast, free MBP did not  bind and 
was recovered in  the flow-through fraction. The sodium chlo- 
ride concentration  required for peak  elution  was  determined to 
provide a measure of relative affinity. The fusion proteins 
bound to heparin-Sepharose with highest to lowest relative 
affinity in  the following order: wild-type (590 mM NaC1) > AA+ 
helix (500 mM NaC1) > AH helix (410 mM NaC1) > AA+ helix/AH 
helix (260 mM NaC1). 
Altered PCI H Helix Synthetic Peptides-The PC1 fusion pro- 
tein  study directed our focus to  the H helix of PCI. To test if 
certain basic residues in  the H  helix may play  a more promi- 
nent role than  others  in  the  PCI-heparin  interaction,  synthetic 
peptides  were  assembled corresponding to PCI-(264-283) 
(SEKTLLKWL_KMFmQLELY)  in which each Lys and Arg 
was substituted individually with Glu. The  heparin binding 
properties of the peptides  were  assessed in competition assays 
and shown to decrease the  rate of proteinase  inhibition in a 
dose-dependent manner (Fig. 3A), and  they  generated sigmoi- 
dal dose-response curves like those  obtained for the PC1 fusion 
proteins (data not shown). All the  altered peptides were less 
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FIG. 3. Effect of altered PC1 H helix peptides  on  interaction 
with  heparin. A, increasing concentrations of the wild-type (wt) H 
helix peptide (PC1-(26&283), S E K T L W L m F m Q L E L Y )  and 
seven altered peptides, in which each Lys and Arg was individually 
substituted  with Glu, were tested for their ability  to interfere  in  hepa- 
rin-accelerated PCI-thrombin and PCI-APC inhibition assays as de- 
scribed under “Experimental  Procedures.” The peptide  concentrations 
required for 50% reduction (1C5J of the inhibition rate  constant  are 
given on the y axis. The  mean of three  separate APC experiments  and 
two thrombin  experiments is reported. B ,  peptides were loaded onto a 
heparin-Sepharose column (2-ml bed volume) equilibrated in 50 mM 
phosphate buffer, pH 7.4. They were eluted with a 20-ml gradient of 
0-750 mM NaCl in phosphate buffer at  0.5 mumin  and at room temper- 
ature  with detection at 214 nm. Conductivity (microsiemens (rnS)) mea- 
surements were made for the peak  elution  fraction, and  the  mean of two 
to eight  separate  runs for each  peptide is shown. 
competitive, requiring higher concentrations than the wild- 
type H helix peptide (IC5o = 5 p ~ )  to get  the  same degree of 
interference (Fig. 3A). In  particular, H helix  peptide R269E was 
the  least competitive for both APC (ICEo = 45 PM) and  thrombin 
(ICEo = 30 p ~ )  inhibition by PCI-heparin.  Furthermore, a sim- 
ilar  trend  was  seen with the  altered H helix peptides when 
assessed for heparin-Sepharose  binding (Fig.  3B). 
Site-directed  Mutagenesis of H Helix Basic  Residues  in Full- 
length rPCI-The role of specific basic  amino  acids in  the H 
helix region of PC1 was  further  assessed  using full-length ac- 
tive rPCI produced by a  Baculovirus  expression  system. Two H 
helix double mutants were generated by replacing Arg-269 and 
Lys-270 with Ala (R269A:K270A rPCI)  and Lys-276 and Lys- 
277 with Ala (K276AK277A rPCI).  The H helix mutants were 
compared with wild-type rPCI for their  heparin binding prop- 
erties. Wild-type rPCI  eluted from heparin-Sepharose at 630 
mM NaC1. Both  R269AR270A and K276A:K277A rPCI showed 
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reduced relative heparin-Sepharose binding, both eluting at  
460 mM NaCl (Table I). 
Second-order rate  constants for APC and  thrombin inhibition 
by rPCIs were  determined in  the absence and presence of in- 
creasing concentrations of heparin. Wild-type rPCI  and both H 
helix substitution  mutants yielded typical  bell-shaped heparin 
template curves  (Fig. 4). APC inhibition in  the absence of hep- 
arin yielded rate  constants of 4.71 x lo4, 4.80 x lo4,  and 3.90 X 
lo4 M” min” for wild-type, R269A:K270A, and K276AK277A 
rPCI, respectively. In  the presence of optimal heparin concen- 
trations, APC inhibition rates for wild-type, R269A:K270A, and 
K276AK277A rPCI were accelerated 32-, 15, and 39-fold, re- 
spectively (Fig. 4 and Table I). In the absence of heparin, 
thrombin inhibition rates for wild-type, R269A:K270A, and 
K276A:K277ArPCI were 1.11 x lo6, 0.97 x lo6, and 0.79 x lo6 
M-’ min-I, respectively. In  the presence of optimal heparin con- 
centrations, thrombin inhibition rates for wild-type, R269A: 
K270A, and K276AK277A rPCI were stimulated 27-, 11-, and 
32-fold, respectively (Fig. 4 and Table 1). For both APC and 
thrombin inhibition, R269A:R270A and K276A:K277A rPCI re- 
quired more heparin to  reach  the maximal  inhibition rate  than 
did wild-type rPCI. 
DISCUSSION 
We utilized three approaches to  assess  the role of the H helix 
as a putative heparin-binding site  in PCI.  A  recombinant run- 
cated PC1 fusion protein was shown to  interfere  in  heparin- 
accelerated proteinase inhibition and to bind heparin-Sepha- 
rose. Deletion mutagenesis showed that  the H helix played a 
greater role than  the A+ helix in  heparin binding by the PC1 
fusion  protein and  supports  the hypothesis that  the H helix is 
an  important  heparin-binding  site  in PCI. PC1 H helix peptides 
were  also shown to bind heparin  in competition assays.  Sub- 
stitution of specific basic residues with Glu reduced heparin 
binding by the peptides compared with  the wild-type peptide. 
The  peptide study  further implies the  importance of electro- 
static  interactions  in  PCI-heparin b ding and  indicates  in  par- 
ticular  that Arg-269 may be especially important. These results 
refine and extend  previous reports  that implicated the H helix 
as a putative  heparin-binding  site  in PCI. 
The 7 basic residues  in  the H helix region can be grouped into 
two clusters  that  have homology to  two heparin-binding con- 
sensus sequences  (19), and Arg-269 is  in  the  first cluster. The 
peptide data do not provide compelling evidence for the impor- 
tance of one basic cluster or consensus  sequence over the other. 
To address  that  question, we generated full-length active rPCI 
and two H helix double substitution  mutants corresponding to  
adjacentbasicresiduesineachcluster,R269A:K27OAandK276A 
K277ArPCI.  Arginine  278  was  not mutated  in  rPCI because ( a )  
a basic residue is conserved in  that position in  many  serpins 
(111, (b)Arg-278  is  at  the boundary of the next exon, and  (c)  an 
a-helical wheel plot of PCI-(264-283) predicts that Arg-278 lies 
on the opposite face of a helix to  the  other basic residues (12). 
In heparin-accelerated APC and thrombin inhibition assays, 
R269A:K270A and K276A:K277A rPCI  required more heparin 
to reach the maximal  inhibition rate compared with wild-type 
rPCI, consistent  with their reduced relative affinity for hepa- 
rin-Sepharose. However, K276A:K277A rPCI achieved essen- 
tially the same maximal heparin acceleration as wild-type 
rPCI, whereas R269AK270A rPCI exhibited a markedly re- 
duced heparin  stimulation. These results indicate that while 
both Arg-269 and/or Lys-270 and Lys-276 and/or Lys-277 ap- 
pear to contribute to  overall heparin binding by PCI, only Arg- 
269 and/or Lys-270 is  required for the maximal  heparin-accel- 
erated  proteinase inhibition  response.  These  full-length rPCI 
mutants  suggest  that reduced heparin affinity does not neces- 
sarily  result  in reduced  heparin-accelerated proteinase inhibi- 
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H helix  mutants. The rate ofAF’C (A) and thrombin ( B )  inhibition by 
FIG. 4. Heparin-accelerated  proteinase  inhibition  by rPCI and 
wild-type rPCI (0) and by rPCI H helix substitution mutants R269A 
K270A ( 0 ) and K276AK277A (0) was measured as a function of hep- 
arin concentration as described under “Experimental Procedures.” The 
mean inhibition rate constants (k,) from three  separate AF’C experi- 
ments and four separate thrombin experiments are reported. 
tion. PC1 binding  to  heparin may  include  random  association 
events,  not  just  the productive binding of serpin  to  heparin  that 
catalyzes proteinase inhibition. Therefore, it is possible that 
some basic residues  are  required for the “optimal alignment” of 
PC1 on the  heparin molecule, while others only contribute  to 
the overall “tightness” of binding. 
A role for the H helix in  heparin binding to  PC1 is  in  sharp 
contrast  to  that  in  antithrombin  and  heparin cofactor 11. Using 
a combination of chemical modification studies, analysis of 
natural human variants, and site-directed mutagenesis, the 
heparin-binding  site  in  antithrombin  and  heparin cofactor I1 
has been localized primarily to the D helix, with additional 
contributions by residues  in  the A helix for antithrombin (26- 
31). The conserved distribution of basic residues  in  the D hel- 
ices of antithrombin  and  heparin cofactor I1 is conspicuously 
absent  in PC1 (Fig. 5). PCI’s C1  and D helices collectively con- 
tain 4 basic residues,  but a synthetic peptide  corresponding to 
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FIG. 5. Amino acid sequence  alignment of the putative hepa- 
rin-binding sites in heparin-binding serpins. Selected sequences of 
PCI, antithrombin (AT), and heparin cofactor  I1 (HCII)  are aligned with 
the sequence of cy,-proteinase inhibitor ( a l P I ) ,  a non-heparin-binding 
serpin, as described by Huber and Carrel1 (11). Basic residues are 
circled  for emphasis. Residues implicated in heparin binding by anti- 
thrombin (reviewed in Refs.  26 and 27) and  in hepariddermatan sulfate 
binding by heparin cofactor  I1  (28-31) are shaded. 
(12). The  basic charge  density  in  the H helix of PC1 is  greater 
than  that  in  antithrombin,  heparin cofactor 11, and  qprotein- 
ase inhibitor (Fig. 5). Interestingly, acidic residues in anti- 
thrombin  align with  most of the basic residues  in  the H helix of 
PCI. 
The location of  PCI’s primary  heparin-binding  site  in a posi- 
tion different  from the heparin-binding sites  in  antithrombin 
and  heparin cofactor I1 may help explain PCI’s more modest 
response to  heparin.  Under identical thrombin inhibition assay 
conditions, optimal heparin concentrations elicited a 9000-fold 
rate  increase for heparin cofactor 11, a 2500-fold rate increase 
for antithrombin,  but only a 15-fold rate  enhancement for PC1 
(18). This difference in  rate  enhancement does not correlate 
with  serpin-heparin affinity (18). Since heparin  acts  as a tem- 
plate  to bind  both serpin  and proteinase, the “orientation” of 
the  serpin reactive site  and  the  proteinase active site could be 
governed, at least  in  part, by  how the  serpin binds to heparin. 
Binding heparin  through  the H helix instead of the D helix may 
alter the reaction geometry such that PC1 is put in a less 
favorable orientation to react  with  heparin-bound proteinase. 
In summary, we have shown that  the H helix is an  essential 
component of the  heparin-binding  site  in PCI. It  remains to be 
seen  what contribution other  structural regions, such  as  the 
A+, C1, and D helices, or other basic residues  in  the H helix 
make to both heparin  binding  and heparin-accelerated  protein- 
ase inhibition by PCI. 
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